These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 24656089)

  • 1. Lessons from glargine trials: what is the goal fasting glucose with basal insulin?
    Bloomgarden Z; Handelsman Y
    J Diabetes; 2014 Jul; 6(4):271-3. PubMed ID: 24656089
    [No Abstract]   [Full Text] [Related]  

  • 2. Insulin detemir (levemir), a new long-acting insulin.
    Med Lett Drugs Ther; 2006 Jul; 48(1238):54-5. PubMed ID: 16841022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More satisfied, but why? A pooled patient-level analysis of treatment satisfaction following the initiation of insulin glargine vs. comparators in insulin-naïve patients with type 2 diabetes mellitus.
    Polonsky W; Traylor L; Wei W; Shi R; Ameer B; Vlajnic A; Nicolucci A
    Diabetes Obes Metab; 2014 Mar; 16(3):255-61. PubMed ID: 24028669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basal insulin analogues in the management of diabetes mellitus: What progress have we made?
    Owens DR; Matfin G; Monnier L
    Diabetes Metab Res Rev; 2014 Feb; 30(2):104-19. PubMed ID: 24026961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Basal insulin has a "neutral effect" on cardiovascular events].
    Overbeck P
    MMW Fortschr Med; 2012 Jun; 154(12):24. PubMed ID: 22880290
    [No Abstract]   [Full Text] [Related]  

  • 6. Insulin glargine dosing before next-day surgery: comparing three strategies.
    Rosenblatt SI; Dukatz T; Jahn R; Ramsdell C; Sakharova A; Henry M; Arndt-Mutz M; Miller V; Rogers K; Balasubramaniam M
    J Clin Anesth; 2012 Dec; 24(8):610-7. PubMed ID: 23122972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The diabetologist/cardiologist debate: a meeting of the minds.
    Mohamed F; Aalbers J
    Cardiovasc J Afr; 2012 Mar; 23(2):115-7. PubMed ID: 22447480
    [No Abstract]   [Full Text] [Related]  

  • 8. Insulin degludec--the impact of a new basal insulin on care in type 2 diabetes.
    Khunti K; Cos X; Rutten G
    Prim Care Diabetes; 2014 Jul; 8(2):119-25. PubMed ID: 24207030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Early insulin therapy in type 2 diabetes?].
    Birkeland KI
    Tidsskr Nor Laegeforen; 2012 Oct; 132(19):2151-2. PubMed ID: 23076480
    [No Abstract]   [Full Text] [Related]  

  • 10. [Diabetes mellitus type 1 and 2. Flexible therapy with insulin degludec].
    Rausch R
    Med Monatsschr Pharm; 2014 Jul; 37(7):273-4. PubMed ID: 25065174
    [No Abstract]   [Full Text] [Related]  

  • 11. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study.
    Fischer JS; McLaughlin T; Loza L; Beauchamp R; Schwartz S; Kipnes M
    Curr Med Res Opin; 2004 Nov; 20(11):1703-10. PubMed ID: 15537471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan.
    Bakiner O; Ertorer ME; Bozkirli E; Tutuncu NB; Demirag NG
    Acta Diabetol; 2009 Mar; 46(1):63-5. PubMed ID: 18825302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: results of the PARADIGM study.
    Bowering K; Reed VA; Felicio JS; Landry J; Ji L; Oliveira J
    Diabet Med; 2012 Sep; 29(9):e263-72. PubMed ID: 22672081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy.
    Hirsch IB; Buse JB; Leahy J; McGill JB; Peters A; Rodbard HW; Rubin RR; Skyler JS; Verderese CA; Riddle MC
    Diabetes Obes Metab; 2014 Mar; 16(3):206-14. PubMed ID: 23711193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of optimal basal insulin glargine dose requirement in Indian population as an add on therapy to oral hypoglycaemic agents to achieve target fasting blood glucose levels.
    Agarwal SK; Singh BK; Wadhwa R
    J Indian Med Assoc; 2013 Sep; 111(9):626-8. PubMed ID: 24968533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes?
    Maiorino MI; Petrizzo M; Capuano A; Giugliano D; Esposito K
    Expert Opin Biol Ther; 2014 Jun; 14(6):799-808. PubMed ID: 24673155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Learning from ORIGIN.
    Bloomgarden ZT
    J Diabetes; 2012 Sep; 4(3):191-2. PubMed ID: 22716648
    [No Abstract]   [Full Text] [Related]  

  • 18. ORIGIN trial shows safety and efficacy of insulin glargine: no adverse cardiovascular outcomes after a 6.2-year follow up of early insulin use.
    Lombard L; Distiller L; Aalbers J
    Cardiovasc J Afr; 2012 Jul; 23(6):357-8. PubMed ID: 23091824
    [No Abstract]   [Full Text] [Related]  

  • 19. An update on the long-acting insulin analogue glargine.
    Thisted H; Johnsen SP; Rungby J
    Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):1-11. PubMed ID: 16867163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating to target in type 2 diabetes: the BEGIN trial programme.
    Wangnoo SK; Chowdhury S; Rao PV
    J Assoc Physicians India; 2014 Jan; 62(1 Suppl):21-6. PubMed ID: 25330628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.